Lisata Therapeutics announces completion of enrollment in Phase 2b ASCEND trial

Lisata Therapeutics announced that a critical milestone has been achieved with the completion of enrollment in the Phase 2b ASCEND study of its novel agent, LSTA1, for the treatment of metastatic pancreatic ductal adenocarcinoma. Lisata expects top-line data from the 95 patients assigned to Cohort A of the study to be reported in the fourth quarter of 2024 and the complete data set of all 155 patients from the study by mid-2025. “The completion of enrollment in ASCEND is a vital step in the development of LSTA1; exceeding the original enrollment completion expectations and, as a result, accelerating the expected timeline for seminal data by nearly 12 months,” stated David J. Mazzo, PhD, President and Chief Executive Officer of Lisata. “This speaks to the tremendous effort on the part of AGITG and CTC as well as the unmet need of patients with mPDAC. We believe LSTA1 has the potential to transform the treatment landscape for this and many other devastating solid tumor cancers. We look forward to reporting Cohort A top-line results from this study in the fourth quarter of next year, which, if positive, will be used to explore accelerated approval applications with regulatory bodies around the world.”